{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:38:37Z","timestamp":1777516717541,"version":"3.51.4"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cent Nerv Syst Dis"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trials comparing the efficacy of ocrelizumab (OCR) with other disease-modifying therapies (DMTs) other than interferon (IFN) \u03b2-1a in relapsing multiple sclerosis (RMS) are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the treatment effect of OCR vs six DMTs\u2019 (IFN \u03b2-1a, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, natalizumab) treatment pathways used in clinical practice by combining clinical trial and real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient-level data from OPERA trials and open-label extension phase, and from the German NeuroTransData (NTD) MS registry, were used to build 1:1 propensity score-matched (PSM) cohorts controlling for seven baseline covariates, including brain imaging activity. Efficacy outcomes were time to first relapse and time to 24-week confirmed disability progression over 5.5\u00a0years of follow-up. Intention-to-treat analysis using all outcome data irrespective of treatment switch was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analyses included 611 OPERA patients and 7141 NTD patients. We built 12 paired-matched cohorts (six for each outcome, two for each DMT) to compare efficacy of OCR in OPERA with each DMT treatment pathway in NTD. Post-matching, baseline covariates and PS were well balanced (standardized mean difference &lt;.2 for all cohorts). Over 5.5\u00a0years, patients treated with OCR showed a statistically significant reduction in the risk of relapse (hazard ratios [HRs] .30 to .54) and disability progression (HRs .51 to .67) compared with all index therapies and their treatment switching pathways in NTD. Treatment switch and\/or discontinuation occurred frequently in NTD cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OCR demonstrates superiority in controlling relapses and disability progression in RMS compared with real-world treatment pathways over a 5.5-year period. These analyses suggest that high-efficacy DMTs and high treatment persistence are critical to achieve greatest clinical benefit in RMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>OPERA I (NCT01247324), OPERA II (NCT01412333)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795735241260563","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:46:56Z","timestamp":1726274816000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-0481","authenticated-orcid":false,"given":"Erwan","family":"Muros-Le Rouzic","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanic","family":"Heer","sequence":"additional","affiliation":[{"name":"PricewaterhouseCoopers AG, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Yiu","sequence":"additional","affiliation":[{"name":"Roche Products Limited, Welwyn Garden City, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Tozzi","sequence":"additional","affiliation":[{"name":"PricewaterhouseCoopers AG, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-8196","authenticated-orcid":false,"given":"Stefan","family":"Braune","sequence":"additional","affiliation":[{"name":"NeuroTransData GmbH, Neuburg an der Donau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"van H\u00f6vell","sequence":"additional","affiliation":[{"name":"PricewaterhouseCoopers AG, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnfin","family":"Bergmann","sequence":"additional","affiliation":[{"name":"NeuroTransData GmbH, Neuburg an der Donau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Model","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licinio","family":"Craveiro","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the NTD study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"bibr1-11795735241260563","unstructured":"European Medicines Agency. Ocrevus [Summary of product characteristics], https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. (2021, accessed January 18, 2021). [Not Available in CrossRef]."},{"key":"bibr2-11795735241260563","unstructured":"Genentech. Ocrevus (Ocrelizumab) [Full prescribing information], https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. (2020, accessed January 20, 2020)."},{"key":"bibr3-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"bibr4-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2021.08.003"},{"key":"bibr5-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103760"},{"key":"bibr6-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00212-5"},{"key":"bibr7-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09395-w"},{"key":"bibr8-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.040"},{"key":"bibr9-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042480"},{"key":"bibr10-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211019649"},{"key":"bibr11-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007938"},{"key":"bibr12-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211021177"},{"key":"bibr13-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.188"},{"key":"bibr14-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"bibr15-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012777"},{"key":"bibr16-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221085733"},{"key":"bibr17-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9083-5"},{"key":"bibr18-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10226-6"},{"key":"bibr19-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01106-6"},{"key":"bibr20-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02738-7"},{"key":"bibr21-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000878"},{"key":"bibr22-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103412"},{"key":"bibr23-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010376"},{"key":"bibr24-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"bibr25-11795735241260563","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2021.633427"},{"key":"bibr26-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooac017"},{"key":"bibr27-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09248-6"},{"key":"bibr28-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2007.07.001"},{"key":"bibr29-11795735241260563","doi-asserted-by":"publisher","DOI":"10.2165\/11206430-000000000-00000"},{"issue":"12","key":"bibr30-11795735241260563","first-page":"1330","volume":"93","author":"Zhu C","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bibr31-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01623-8"},{"key":"bibr32-11795735241260563","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.647811"},{"key":"bibr33-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102974"},{"key":"bibr34-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320902488"},{"key":"bibr35-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000487"},{"key":"bibr36-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4905"},{"key":"bibr37-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"bibr38-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010128"},{"key":"bibr39-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.2738"},{"issue":"5","key":"bibr40-11795735241260563","first-page":"639","volume":"27","author":"Engmann NJ","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr41-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11320-7"},{"key":"bibr42-11795735241260563","unstructured":"Butzkueven H, Spelman T, Ozakbas S, et al. Real-world experience with ocrelizumab in the MSBase Registry. In: 8th Joint ACTRIMS-ECTRIMS Meeting, virtual. September 11\u201313, 2020, P0909. MSVirtual2020."},{"key":"bibr43-11795735241260563","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.863105"},{"key":"bibr44-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwaa243"},{"key":"bibr45-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052953"},{"key":"bibr46-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2056"},{"key":"bibr47-11795735241260563","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011242"}],"container-title":["Journal of Central Nervous System Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795735241260563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795735241260563","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795735241260563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:59:45Z","timestamp":1777391985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795735241260563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":47,"alternative-id":["10.1177\/11795735241260563"],"URL":"https:\/\/doi.org\/10.1177\/11795735241260563","relation":{},"ISSN":["1179-5735","1179-5735"],"issn-type":[{"value":"1179-5735","type":"print"},{"value":"1179-5735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"article-number":"11795735241260563"}}